BioSpace News Archive

Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE ® (Verteporfin for Injection).

CureVac N.V. today announced that Myriam Mendila has taken up her role as CureVac’s Chief Development Officer, as previously announced.

BioStem Technologies Inc. today announced the appointment of Michael Sylvester as Vice President of Sales and Neal Bhattcharya as Vice President of Marketing.

Annovis Bio, Inc. announced today the filing of a patent application that extends the breadth of its platform from neurodegenerative to neuropsychiatric indications: “Treatment of mental illness via administration of buntanetap and analogues.”

Apyx Medical Corporation today announced it has submitted a 510(k) premarket notification (“510(k) submission”) for Renuvion APR Handpiece to the U.S. Food and Drug Administration (“FDA”), supported by a clinical study and real-world evidence.

Enveric Biosciences today announced that CEO Joseph Tucker, Ph.D., will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City.

Cybin Inc. is pleased to announce that it has received approval from an independent ethics committee in the Netherlands to initiate first-in-human dosing of its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule CYB004 through a protocol amendment to its ongoing CYB004-E Phase 1 trial.

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the Guggenheim Healthcare Talks Oncology Conference in New York, NY.

Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI) plans to announce its fourth quarter and full year 2022 financial and operating results after the market closes on Wednesday, February 22, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Cue Biopharma, Inc. (Nasdaq: CUE) announced today that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference.